W Keith Miskimins
Overview
Explore the profile of W Keith Miskimins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhuang Y, Coppock J, Haugrud A, Lee J, Messerli S, Miskimins W
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672607
Elevated glucose uptake and production of lactate are common features of cancer cells. Among many tumor-promoting effects, lactate inhibits immune responses and is positively correlated with radioresistance. Dichloroacetate (DCA) is...
2.
Zhuang Y, Haugrud A, Schaefer M, Messerli S, Miskimins W
Front Oncol
. 2023 Aug;
13:1225220.
PMID: 37583931
Background: Nicotinamide adenine dinucleotide (NAD+) is vital for not only energy metabolism but also signaling pathways. A major source of NAD+ depletion is the activation of poly (ADP-ribose) polymerase (PARP)...
3.
Zylla J, Hoffman M, Plesselova S, Bhattacharya S, Calar K, Afeworki Y, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406526
This study investigates the effects of a dual selective Class I histone deacetylase (HDAC)/lysine-specific histone demethylase 1A (LSD1) inhibitor known as 4SC-202 (Domatinostat) on tumor growth and metastasis in a...
4.
Powell S, Mazurczak M, Dib E, Bleeker J, Geeraerts L, Tinguely M, et al.
Invest New Drugs
. 2022 Mar;
40(3):622-633.
PMID: 35312941
Chemoradiotherapy (CRT) for locally-advanced head and neck squamous cell carcinoma (LA-HSNCC) yields 5-year survival rates near 50% despite causing significant toxicity. Dichloroacetate (DCA), a pyruvate dehydrogenase kinase metabolic inhibitor, reduces...
5.
Verma A, Messerli S, Miskimins W
Oncotarget
. 2020 May;
11(17):1493-1504.
PMID: 32391119
Intratumoral lactate production negatively correlates with survival and tumor clearance in the setting of human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV-positive OPSCC). Robust anti-tumor immune activity is required for...
6.
Hoffman M, Zylla J, Bhattacharya S, Calar K, Hartman T, Bhardwaj R, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32210076
Central nervous system atypical teratoid/rhabdoid tumors (ATRTs) are rare and aggressive tumors with a very poor prognosis. Current treatments for ATRT include resection of the tumor, followed by systemic chemotherapy...
7.
Hsia C, Messerli S, Miskimins W
Cell Biochem Biophys
. 2019 May;
77(2):121-122.
PMID: 31093886
No abstract available.
8.
Messerli S, Schaefer A, Zhuang Y, Soltys B, Keime N, Jin J, et al.
J Oncol
. 2019 Apr;
2019:3253696.
PMID: 30941174
Of the deaths attributed to cancer, 90% are due to metastasis. Treatments that prevent or cure metastasis remain elusive. Low expression of extracellular superoxide dismutase (EcSOD or SOD3) has been...
9.
Lucido C, Miskimins W, Vermeer P
Cancers (Basel)
. 2018 Dec;
10(12).
PMID: 30513596
Tumor cell metabolism differs from that of normal cells, conferring tumors with metabolic advantages but affording opportunities for therapeutic intervention. Accordingly, metabolism-targeting therapies have shown promise. However, drugs targeting singular...
10.
Lucido C, Callejas-Valera J, Colbert P, Vermeer D, Miskimins W, Spanos W, et al.
Oncogenesis
. 2018 Oct;
7(10):81.
PMID: 30297705
The incidence of human papillomavirus-associated head and neck squamous cell carcinoma (HPV[ + ] HNSCC) is rapidly increasing. Although clinical management of primary HPV( + ) HNSCC is relatively successful,...